Ledipasvir
|
|
|
- CAS-Nr.
- 1256388-51-8
- Englisch Name:
- Ledipasvir
- Synonyma:
- GS 588;GS5885;CS-948;GS 5885;GS-5885;Ledipasvir;Leidipawei;332382-54-7;gs-5885/gs5885;Ledipasvir API
- CBNumber:
- CB52666650
- Summenformel:
- C49H54F2N8O6
- Molgewicht:
- 889
- MOL-Datei:
- 1256388-51-8.mol
|
Ledipasvir Eigenschaften
- Schmelzpunkt:
- 186-190oC
- Dichte
- 1.42±0.1 g/cm3(Predicted)
- storage temp.
- -20°C Freezer
- L?slichkeit
- DMSO (Slightly, Heated), Methanol (Slightly)
- pka
- 11.20±0.10(Predicted)
- Aggregatzustand
- Solid
- Farbe
- White to Pale Beige
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| S-S?tze: |
24/25 |
|
|
| RIDADR |
3077 |
|
|
| HS Code |
29333990 |
|
|
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitssch?dlich bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 4 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P270, P301+P312, P330, P501 |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
P264, P280, P305+P351+P338,P337+P313P |
| H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizit?t (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
![GHS hazard pictograms]() src="/GHS07.jpg" width="20" height="20" /> |
|
|
| Sicherheit |
| P261 |
Einatmen von Staub vermeiden. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen. |
|
Ledipasvir Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Ledipasvir is a potent NS5A inhibitor that is approved for use in
combination with sofosbuvir, a nucleotide inhibitor of viral polymerase,
for the treatment of chronic hepatitis C virus genotype 1
infection. This combination was discovered and developed
at Gilead Sciences and is marketed as the fixed combination with
brand name of Harvoni.
Verwenden
Ledipasvir is most commonly used in combination with sofosbuvir for treatment in chronic hepatitis C genotype 1 patients. It inhibits an important viral phosphoprotein, NS5A, which is involved in viral replication, assembly, and secretion.
Definition
ChEBI: Ledipasvir is a benzimidazole derivative that is used in combination with sofosbuvir (under the trade name Harvoni) for the treatment of chronic hepatitis C genotype 1 infection. It has a role as an antiviral drug and a hepatitis C protease inhibitor. It is a carbamate ester, a L-valine derivative, a bridged compound, a carboxamide, a benzimidazole, a member of fluorenes, an organofluorine compound, a member of imidazoles, a N-acylpyrrolidine and an azaspiro compound.
Mode of action
Ledipasvir is a potent inhibitor of HCV nonstructural protein 5A (NS5A), a viral phosphoprotein that plays an important but poorly understood role in viral replication, assembly, and secretion. ;Ledipasvir is approved for the treatment of genotype 1 HCV. Its safety and efficacy have not been fully established for genotypes 2 through 6. NS5A amino acid substitutions Y93H (in genotypes 1a and 1b) and Q30E (in genotype 1a) significantly reduce susceptibility to ledipasvir in cell culture and in clinical studies. Other amino acid substitutions observed in virologic treatment failures are K24R, M28T/V, Q30H/K/L (genotype 1a), and L31V/M/I (genotype 1b). Viruses with these resistance-associated mutations remained susceptible to sofosbuvir.
Ledipasvir Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Carbamic acid, N-[(1S)-2-methyl-1-[[(1R,3S,4S)-3-[6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzimidazol-2-yl]-2-azabicyclo[2.2.1]hept-2-yl]carbonyl]propyl]-, methyl ester
1,2-Pyrrolidinedicarboxylicacid,1-methylester,(2S)-(9CI)
ledipasvir interMediate
ledipasvir interMediate
Valine, N-(methoxycarbonyl)-
Downstream Produkte
Ledipasvir Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 270)Lieferanten
1256388-51-8()Verwandte Suche:
- GS 5885
- GS5885
- GS-5885
- Ledipasvir
- GS-5885/Ledipasvir
- gs-5885/gs5885
- Ledipasvir / GS 5885
- GS 588
- HY-15602 (GS-5885
- Solid dispersion of ledipasvir
- Ledipasvir (API, Amorphous)
- Ledipasvir: copovidone solid dispersion 1:1
- N-[(1S)-1-[[(6S)-6-[5-[9,9-difluoro-7-[2-[(1R,3S,4S)-2-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-2-azabicyclo[2.2.1]hept-3-yl]-1H-benzimidazol-6-yl]-9H-fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl]carbonyl]-2-methylpropyl]-carbamic acid methyl ester
- Leidipawei
- N-[(1S)-1-[[(6S)-6-[5-[9,9-difluoro-7-[2-[(1R,3S,4S)-2-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxoButyl]-2-azabicyclo[2.2.1]hept-3-yl]-1H-benzimidazol-6-yl]-9H-fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl]carbonyl]-2-methylpropyl]-carbamic
- Ledipasvir API
- N-[(1S)-1-[[(6S)-6-[5-[9,9-Difluoro-7-[2-[(1R,3S,4S)-2-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-2-azabicyclo[2.2.1]hept-3-yl]-1H-benzimidazol-6-yl]-9H-fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspi
- Ledipasvir, 98%, HCV NS5A polymerase inhibitor
- GS 5885;GS-5885;GS5885
- CS-948
- Carbamic acid, N-[(1S)-1-[[(6S)-6-[5-[9,9-difluoro-7-[2-[(1R,3S,4S)-2-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-2-azabicyclo[2.2.1]hept-3-yl]-1H-benzimidazol-6-yl]-9H-fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl]carbonyl]-2-methylpropyl]-, methyl ester
- Ledipasvir (10mM in DMSO)
- methyl((S)-1-((S)-6-(5-(9,9-difluoro-7-(2-((1R,3S,4S)-2-((methoxycarbonyl)-L-valyl)-2-azabicyclo[2.2.1]heptan-3-yl)-1H-benzo[d]imidazol-6-yl)-9H-fluoren-2-yl)-1H-imidazol-2-yl)-5-azaspiro[2.4]heptan-5-yl)-3-methyl-1-oxobutan-2-yl)carbamate
- Ledipasvir 13C2 D6Q: What is
Ledipasvir 13C2 D6 Q: What is the CAS Number of
Ledipasvir 13C2 D6 Q: What is the storage condition of
Ledipasvir 13C2 D6 Q: What are the applications of
Ledipasvir 13C2 D6
- Ledipasvir D16
- Ledipasvir D8Q: What is
Ledipasvir D8 Q: What is the CAS Number of
Ledipasvir D8 Q: What is the storage condition of
Ledipasvir D8 Q: What are the applications of
Ledipasvir D8
- LedipasvirQ: What is
Ledipasvir Q: What is the CAS Number of
Ledipasvir Q: What is the storage condition of
Ledipasvir Q: What are the applications of
Ledipasvir
- 332382-54-7
- 1H-Pyrazol-5-amine,1-(6-methylethyl)-
- Ledipasvir undefined salt form
- 1256388-51-8
- 256388-51-8
- C49H54F2N8O6
- Inhibitors
- API
